Medulloblastoma is a type of malignant brain tumour that occurs in neuroepithelial tissue in children. Based on age, disease spread, and degree of surgical resection of the disease, medulloblastoma is stratified into standard and high-risk categories. Increased intracranial pressure and cerebellar dysfunction along with the headache, vomiting, and ataxia, are observed in patients with medulloblastoma. The cause of medulloblastoma is still unknown but some genes are involved in pathogenesis of the disease such as inhibitor of the sonic hedgehog pathway SUFU (10q24.32), chromatin regulators KDM6A (Xp11.2) and N-CoR complex genes BCOR (Xp11.4), the RNA helicase DDX3X (Xp11.3-p11.23) and parkinson's disease genes KMT2D (12q13.12), SMARCA4 (19p13.3), MYCN (2p24.3), and TP53 (17p13.1). The University of Florida is in the process of developing TTRNA-xALT for the treatment of medulloblastoma. Oncurious NV is in the process of developing TB-403 as an angiogenesis inhibitor for the treatment of medulloblastoma. Some of the companies having the pipeline of medulloblastoma include Oncurious NV, Ignyta, Inc., Pinnacle Biologics, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.